D&D PharmaTech Co.
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's … Read more
D&D PharmaTech Co. (347850) - Total Liabilities
Latest total liabilities as of March 2025: ₩24.61 Billion KRW
Based on the latest financial reports, D&D PharmaTech Co. (347850) has total liabilities worth ₩24.61 Billion KRW as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
D&D PharmaTech Co. - Total Liabilities Trend (2022–2024)
This chart illustrates how D&D PharmaTech Co.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
D&D PharmaTech Co. Competitors by Total Liabilities
The table below lists competitors of D&D PharmaTech Co. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MegaChips Corporation
F:MHC
|
Germany | €67.13 Billion |
|
Hanjin Kal
KO:18064K
|
Korea | ₩953.31 Billion |
|
Postal Realty Trust Inc
NYSE:PSTL
|
USA | $386.71 Million |
|
Shenzhen Tatfook Tech
SHE:300134
|
China | CN¥1.85 Billion |
|
Jiangsu Longda Superalloy Co. Ltd. A
SHG:688231
|
China | CN¥1.06 Billion |
|
Dogus Otomotiv Servis ve Ticaret AS
IS:DOAS
|
Turkey | TL58.84 Billion |
|
Anhui Huilong Agricultural Means of Production Co Ltd
SHE:002556
|
China | CN¥7.19 Billion |
|
Hyperion Metals Limited
PINK:TAOFF
|
USA | $12.59 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down D&D PharmaTech Co.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.80 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how D&D PharmaTech Co.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for D&D PharmaTech Co. (2022–2024)
The table below shows the annual total liabilities of D&D PharmaTech Co. from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩27.39 Billion | -15.87% |
| 2023-12-31 | ₩32.55 Billion | -61.34% |
| 2022-12-31 | ₩84.20 Billion | -- |